DnB Asset Management
VRDN icon

DnB Asset Management’s Viridian Therapeutics VRDN Stock Holding History

DnB Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$657K Buy
35,775
+19,791
+124% +$319K ﹤0.01% 709
2026
Q1 		$313K Sell
15,984
-4,436
-22% -$132K ﹤0.01% 957
2025
Q4 		$635K Buy
+20,420
New +$560K ﹤0.01% 667

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

DnB Asset Management's VRDN Position: Q2 2026 in Review

DnB Asset Management increased its Viridian Therapeutics (VRDN) stake by 124% in Q2 2026, buying an estimated $319K and bringing the position to 35,775 shares worth $657K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

DnB Asset Management first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • DnB Asset Management held 35,775 shares of Viridian Therapeutics worth $657K as of Q2 2026.
  • DnB Asset Management bought 19,791 Viridian Therapeutics shares in Q2 2026, an estimated $319K.
  • Viridian Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #709 holding.
  • DnB Asset Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.